Andere Sprachen PharmaTher Holdings Ltd.

Aktien

A3CM5J

CA71716H1082

PHRM

Verzögert Canadian Securities Exchange Andere Börsenplätze 17:17:31 07.05.2024			% 5 Tage	% 1. Jan.
0,26 ^CAD	-3,70 %		-1,89 %	-17,46 %

23.04.	PharmaTher Holdings Ltd. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 29. Februar 2024	CI
16.04.	PharmaTher Holdings Ltd. gibt Update zu seinem vorrangigen Original-Kurzantrag für Ketamin	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	01.05.
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine	01.05.
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23.04.
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	18.04.
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16.04.
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	16.04.
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16.04.
PharmaTher Provides Update For PD-001	21.02.
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	21.02.
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	15.02.
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12.02.
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12.02.
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12.02.
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12.02.
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27.01.
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10.01.
PharmaTher Provides Update for Expected FDA Approval of Ketamine	10.01.
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10.01.
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31.10.23
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PharmaTher Holdings Ltd.

Aktien

A3CM5J

CA71716H1082

PHRM

Andere Sprachen

Filter